Danish clinical-stage radiopharmaceuticals company Curasight A/S (Spotlight Stock Market: CURAS) said on Wednesday that it has opened patient enrolment in its phase 1 trial of uTREAT, a targeted radioligand therapy for aggressive brain cancer (glioblastoma).

Based in Copenhagen, the company develops both uTRACE (diagnostic PET imaging) and uTREAT (therapeutic) platforms targeting the Urokinase-type Plasminogen Activator Receptor (uPAR) expressed on many cancer types.

Regulatory, ethical and logistical approvals are in place, and first dosing is expected in the coming weeks. The study forms part of Curasight's broader theranostic strategy of combining diagnosis (uTRACE) and treatment (uTREAT) for uPAR-expressing tumours.

The trial will recruit patients with newly diagnosed or suspected glioblastoma, following prior data indicating approximately 94% of GBM tumours express uPAR. If successful, uTREAT could offer a more targeted alternative to conventional external-beam radiation, potentially reducing damage to healthy brain tissue.